Quince Therapeutics, Inc. (QNCX) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Quince Therapeutics, Inc. (QNCX:NASDAQ), powered by AI.

Current Price
$0.12
P/E Ratio
-0.1
Market Cap
5M
Sector
Healthcare
What is the Quince Therapeutics, Inc. stock price forecast?

Quince Therapeutics, Inc. is currently trading at $0.12. View real-time AI analysis on Alpha Lenz.

What is Quince Therapeutics, Inc. insider trading activity?

View the latest insider trading data for Quince Therapeutics, Inc. on Alpha Lenz.

What is Quince Therapeutics, Inc.'s P/E ratio?

Quince Therapeutics, Inc.'s P/E ratio is -0.1.

Quince Therapeutics, Inc.

NASDAQ · QNCX
$0.12
Ask about Quince Therapeutics, Inc.'s future dividend policy...
Alpha Chat Insight

Quince Therapeutics, Inc. trades at a P/E of -0.1 (undervalued) with modest ROE of -98.6%.

Ask for details

Company Overview

Quince Therapeutics Inc. is a biotechnology company focused on discovering and developing innovative therapies aimed at treating medical conditions with a significant unmet need. By leveraging advanced technologies, the company dedicates its resources towards creating novel therapeutics that address the underlying mechanisms of diseases. Quince Therapeutics operates within the pharmaceutical and biotechnology sector, impacting both the healthcare and life sciences industries. The company's research and development initiatives are crucial in the realm of rare diseases and complex medical disorders, where few effective treatments are currently available. Through strategic partnerships and collaborations, Quince Therapeutics endeavours to translate scientific breakthroughs into practical, patient-centric solutions. In the broader financial market, Quince Therapeutics plays an integral role in driving innovation and progress within the healthcare sector, contributing to advancements that can lead to better patient outcomes and quality of life improvements worldwide. As a biotechnology entity, Quince Therapeutics is integral in the ongoing efforts to bring cutting-edge therapies from concept to clinical reality.

CEODr. Dirk Thye M.D.
SectorHealthcare
IndustryBiotechnology
Employees36

Company Statistics

FY 2024

Profile

$5.35MMarket Cap
$0.00Revenue
0.00Shares Out
36Employees

Margins

N/AGross
N/AEBITDA
N/AOperating
N/APre-Tax
N/ANet

Valuation

-0.09P/E
0.18P/B
N/AEV/Sales
-0.94EV/EBITDA
-0.17P/FCF

Growth (CAGR)

N/ARev 3Yr
N/ARev 5Yr
N/AOp Inc 3Yr
N/AOp Inc 5Yr
N/ANet Inc 3Yr
N/ANet Inc 5Yr

Returns

-40.25%ROA
-98.63%ROE
-25.62%ROIC

Financial Health

$6.21MCash & Cash Equivalents
$78.12MNet Debt
279.75%Debt/Equity
N/AInterest Cov
Alpha Chat Insight

Quince Therapeutics, Inc. trades at a P/E of -0.1 (undervalued) with modest ROE of -98.6%.

Ask for details

Frequently Asked Questions

Quince Therapeutics, Inc. (ticker: QNCX) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 36 employees. Market cap is $5M.

The current price is $0.124 with a P/E ratio of -0.09x and P/B of 0.18x.

ROE is -98.63%.

Alpha Lenz
Singapore
CEO: Kyungtae Kim | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2025 Treasurer. All rights reserved.
Quince Therapeutics, Inc. (Healthcare) Stock Forecast & Analysis $0.12 | Alpha Lenz